The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas

Mechanisms for late-onset neutropenia (LON) after rituximab treatment are poorly defined both for non-Hodgkin lymphoma (NHL) and for autoimmune disorders. We performed a case–control analysis of a prospective cohort of 169 evaluable consecutive rituximab-treated NHL patients to assess cytokines invo...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2021-06, Vol.38 (6), p.70-70, Article 70
Main Authors: Tesfa, Daniel, Sander, Birgitta, Lindkvist, Henric, Nilsson, Christer, Kimby, Eva, Hägglund, Hans, Wahlin, Björn E., Klimkowska, Monika, Palmblad, Jan
Format: Article
Language:English
Subjects:
APRIL
BAFF
G-CSF
Hematology
Immunotherapy
Internal Medicine
Late-onset neutropenia
Medicine
Medicine & Public Health
Monoclonal antibodies
Neutropenia
Neutrophils
Oncology
Original Paper
Pathology
Rituximab
SDF1
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mechanisms for late-onset neutropenia (LON) after rituximab treatment are poorly defined both for non-Hodgkin lymphoma (NHL) and for autoimmune disorders. We performed a case–control analysis of a prospective cohort of 169 evaluable consecutive rituximab-treated NHL patients to assess cytokines involved in neutro- and lymphopoiesis (G-CSF, SDF1, BAFF, APRIL) and inflammation (CRP) as possible LON mechanisms. Fifteen patients (9%) developed LON (peripheral blood /PB/ absolute neutrophil counts /ANC/ 
ISSN:1357-0560
1559-131X
1559-131X
DOI:10.1007/s12032-021-01516-8